Allosteric Bioscience

Executive Summary

Allosteric Bioscience is a San Diego-based biotechnology company founded in 2018 that leverages artificial intelligence, machine learning, and quantum computing to develop novel allosteric modulators for neurological and psychiatric disorders. By targeting allosteric sites, the company aims to achieve greater selectivity and fewer side effects compared to traditional orthosteric drugs. Its platform integrates advanced computational methods to design small molecules, potentially accelerating discovery and reducing failure rates. Although still in early stages with no disclosed funding or clinical candidates, the company's interdisciplinary approach positions it at the forefront of AI-driven drug discovery. The convergence of these technologies could unlock new therapeutic options for conditions such as depression, anxiety, and neurodegenerative diseases, addressing significant unmet medical needs.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data Release for Lead Program30% success
• Q2 2027Series A Funding Announcement40% success
• Q1 2027Strategic Partnership or Licensing Deal with Pharma25% success